Physician profile
Sarah Lang
NPI 1346315116
$3,799.75
in general payments reported to CMS, 2019-2025
13 companies · $216 in 2025
The $216 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.17 · 2020: $28.17 · 2021: $21.00 · 2022: $41.01 · 2023: $85.87 · 2024: $3,352 · 2025: $216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,296 · Travel and Lodging: $737 · Food and Beverage: $621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,296.00 |
| Travel and Lodging | $736.74 |
| Food and Beverage | $620.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,158.46 | 2023-2024 | Krystexxa, Prolia, Evenity |
| Novo Nordisk INC | $159.67 | 2019-2025 | Wegovy, Ozempic |
| Astrazeneca Pharmaceuticals LP | $101.13 | 2024-2025 | Airsupra, Breztri |
| Abbvie INC. | $91.68 | 2021-2023 | |
| Exact Sciences Corporation | $78.56 | 2024-2025 | Cologuard Collection Kit |
| Corcept Therapeutics | $53.45 | 2024 | Korlym |
| Abbott Laboratories | $41.95 | 2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $33.64 | 2022-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $22.48 | 2022 | |
| Glaxosmithkline, LLC. | $18.53 | 2025 | Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.32 | 2024 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $13.13 | 2024 | Eliquis |
| Alfasigma USA, INC. | $12.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.